CD274 and neoplasm: TNBC is more likely to benefit from ICIs therapy than other breast cancer subtypes [84] due to a large number of tumor-infiltrating lymphocytes (TIL), high level of PD-L1 expression and greater number of nonsynonymous mutations, which can generate tumor-specific neoantigens and activate specific T cells, so as to produce antitumor immune responses [85].